New Head-to-Head Data Show TALTZ® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis

    NEXT STORY
    Vir Biotechnology Announces Pricing of Initial Public Offering
    PREV STORY
    GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Mateon Provides Corporate Update and Reports Second Quarter 2016 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), ...

    author_avatar
    NASDAQ Market News

    Urinary Catheters Market to Reach USD 4.18 Billion by 2026; Growing Awareness About Urinary Incontinence to Fuel the Market: Fortune Business Insights

    author_avatar
    NASDAQ Market News

    Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma

    NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology ...

    author_avatar
    NASDAQ Market News